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Cancer is a worldwide health problem. Personalized treatment represents a future
advancement for cancer treatment, in part due to the development of targeted therapeutic
drugs. These molecules are expected to be more effective than current treatments
and less harmful to normal cells. The discovery and validation of new targets are the
foundation and the source of these new therapies. The neurotensinergic system has been
shown to enhance cancer progression in various cancers such as pancreatic, prostate,
lung, breast, and colon cancer. It also triggers multiple oncogenic signaling pathways, such
as the PKC/ERK and AKT pathways. In this review, we discuss the contribution of the
neurotensinergic system to cancer progression, as well as the regulation and mechanisms
of the system in order to highlight its potential as a therapeutic target, and its prospect for
its use as a treatment in certain cancers.
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INTRODUCTION
Cancer is one of the ﬁrst, if not the ﬁrst cause, of death in the
world. Conventional treatment methods include surgery, radio-
therapy, and chemotherapy. In many cases, only a supportive
treatment can be offered to the patient. The last few decades have
been marked by the accumulation of knowledge about the inner
workings of the normal and cancer cell. Thus arose the thera-
peutic arsenal against cancer, and the so-called targeted biological
therapies. Due to these new drugs, great progress has recently
been achieved in the treatment of cancers considered refractory
to previous therapies, including cancers of the liver, kidney, and
melanoma skin. But other tumors, such as breast and lung cancer,
have also greatly beneﬁted from these advances. However, remis-
sions are often transient and do not yet provide deﬁnitive cures of
the patient. In this context the neurotensin system is proposed to
be a candidate for therapeutical development.
Neurotensin (NTS) is a tridecapeptide originally isolated from
calf hypothalamus (Carraway and Leeman, 1973). It acts as neu-
rotransmitter or neuromodulator in the central nervous system
and as a local hormone in the periphery, mainly the gastroin-
testinal tract (Vincent et al., 1999). In the brain, NTS modulates
dopaminergic transmission in the nigrostriatal and mesocorticol-
imbic pathways as well as hormone secretion from the anterior
pituitary (Vincent et al., 1999). It also exerts potent hypothermic
and analgesic effects when injected into the central nervous system
(Popp et al., 2007). NTS has also been related to central nervous
system pathology such as Parkinson disease and schizophrenia
(St-Gelais et al., 2006; Mustain et al., 2011). In the periphery,
NTS is released by endocrine-like N cells predominantly in the
small intestine (Reinecke, 1985). NTS has a dual function, as a
paracrine and endocrine modulator of the digestive tract and as
a growth factor on a variety of normal or cancer cells (Vincent
et al., 1999; Carraway and Plona, 2006). The NTS/NTSR1 complex
has been proposed to contribute to cancer progression because of
the various oncogenic effects induced by NTS in tumors and in
cancer cells from diverse origins (Thomas et al., 2003; Dupouy
et al., 2011). In this review, we elaborate on how the NTS/NTSR1
complex could be developed as a possible target for cancer therapy.
NEUROTENSIN/NEUROTENSIN RECEPTOR COMPLEX
NEUROTENSINERGIC SYSTEM
The biological effects of NTS are known to be mediated through
three receptors, two G protein-coupled receptors, NTSR1 and
NTSR2, and a single transmembrane domain sorting receptor, the
NTSR3 (Vincent et al., 1999; Mazella and Vincent, 2006). NTSR3
is a member of the receptor family related to the yeast sorting
receptor Vps10p (Petersen et al., 1997).
Neurotensin receptor 1, NTSR1
The effects of NTS are primarily transmitted through its high
afﬁnity receptor, the NTSR1 which has a sub-nanomolar afﬁnity
for NTS. This 424 amino acid receptor has been identiﬁed in the
brain and in various cancer cells (Tanaka et al., 1990). The sig-
naling pathways induced by the NTS/NTSR1 complex have been
studied in different cellular types, such as N1E-115, HT-29, and
NTSR1-transfected CHO overexpressing NTSR1. The stimulation
of NTSR1 by its ligand (NTS) leads to activation of phospholipase
C (PLC) via its coupling to the prime Gαq/11 subunit (Wang and
Wu, 1996; Najimi et al., 2002). The activation of PLC leads to the
production of inositol triphosphate (IP3) and diacylglycerol from
membrane phospholipids (PIP2). These two second messengers
induce the activation of PKC and the mobilization of intracellu-
lar calcium which are key oncogenic effectors (Bozou et al., 1986;
Snider et al., 1986; Turner et al., 1990).
www.frontiersin.org January 2013 | Volume 3 | Article 184 | 1
“fendo-03-00184” — 2013/1/12 — 17:45 — page 2 — #2
Wu et al NTS/NTSR1 complex and cancer therapy
Several signaling pathways potentially involved in cell pro-
liferation, survival, migration, and invasion are described after
NTSR1 stimulation. The signaling mechanisms mediating the
effects of neurotensinergic system involve multiple pathways and
are cell-dependent. The NTS-induced PKC/ERK signaling path-
way is the most well studied. The PKC activation stimulated by
NTS/NTSR1 was demonstrated by using broad isotype inhibitors,
such as Gö6976 which speciﬁcally inhibit the conventional PKCs
α and β1 in CHO-NTSR1-transfected cells and in endogenously
NTSR1-expressing cells from colon, lung, and pancreatic cells
(Poinot-Chazel et al., 1996; Seufferlein and Rozengurt, 1996;
Ehlers et al., 2000; Muller et al., 2011). The NTSR1 contribution
in this activation was conﬁrmed by its inhibition by a speciﬁc
NTSR1 antagonist, the SR 489692 (Gully et al., 1993). PKC activa-
tion induce mitogen-activated protein kinase (MAPK) via direct
stimulation of Raf-1, independently of Ras, or by transactiva-
tion of the epidermal growth factor receptor (EGFR) (Guha et al.,
2003). EGFR transactivation by NTS/NTSR1 complex has been
observed in several cell lines. In prostatic cancer PC3 cell line,
NTS activates mitogenesis through EGFR transactivation in a
PKC-dependent pathway, and the stimulation of the Raf–MEK–
ERK. This effect was also PI3 kinase (PI3K)-dependent (Hassan
et al., 2004). NTS also induces a time-dependent increase in Tyr845
EGFR phosphorylation, c-Src phosphorylation and signal trans-
ducer. NTS is also an activator of transcription 5b (Stat5b), a
downstream effector of Tyr845 EGFR phosphorylated (Amorino
et al., 2007). In colonic HT-29 cells, the EGFR tyrosine kinase
inhibitor, geﬁtinib, blocks NTS-stimulated phosphorylation of
both MAPK andAkt, indicating the transactivation of EGFR inde-
pendently of PKC activation. However, in the colonic HCT116
cells, NTS/NTSR1 induces a PKC-dependent MAPK phosphory-
lation and an EGFR metalloproteinase-mediated transactivation,
that is associated with a geﬁtinib-sensitive phosphorylation of the
downstream adaptor protein Shc. The activation of Akt is only
partly inhibited by geﬁtinib, suggesting an additional mechanism
to EGFR transactivation (Muller et al., 2011). The mechanism
of NTS-induced EGFR transactivation is still not clearly eluci-
dated. The release of EGFR ligands-like (TGF-α, Hb-EGF, or
amphiregulin), pre-existing at the plasma membrane, as pro-
ligand, by NTS has been proposed. These ligands are released by
proteolytic cleavage involving enzymes of the metalloproteinase
family, including ADAMS (disintegrin and metalloprotease) and
MMP (matrix metalloproteinase; Sanderson et al., 2006; Zhao
et al., 2007; Kataoka, 2009). Once released, these ligands bind to
EGFR and activate the downstream signaling cascades of EGFR
activation (Hassan et al., 2004). These results suggest a coopera-
tive relationship between the neurotensinergic system and EGFR
pathway.
Activation of MAPK pathway by NTS results in gene transcrip-
tion stimulation, due to transcription factor activation, such as
the induction of the early growth response gene-1 (Egr-1), the
Ets family factors ELK1, and the AP-1 transcription factor family
(Poinot-Chazel et al., 1996; Portier et al., 1998; Ehlers et al., 2000;
Zhao et al., 2007). In colonic HCT166 cells, inhibition of PKC was
shown to block NTS-induced DNA synthesis (Muller et al., 2011).
In a tumor-initiating cell line derived from hepatocellular carci-
noma (HCC) which is characterized by membrane expression of
CD133, addition of exogenous NTS resulted in concomitant up-
regulation of IL-8 and CXCL1 with simultaneous activation of
MAPK and Raf-1, and promotion of angiogenesis, tumorigene-
sis, and self-renewal (Tang et al., 2012). The activation of MAPK
via NTSR1 is mainly associated with uncontrolled cell growth,
which can aggravate the growth of tumors (Harikumar et al., 2010;
Kisfalvi et al., 2010).
Neurotensin also induces RhoGTPases and the non-receptor
kinases focal adhesion kinase (FAK) and Src. Neurotensinergic
system stimulation can modulate the activity of small RhoGT-
Pases Rac1, Cdc42, and RhoA, which are partly responsible for
the dynamics of the cytoskeleton. This modulation has an effect
on cell migration. In the cell line U373 glioblastoma, the NTS
has been associated with the stimulation of the activity of protein
Rac1, RhoA, and Cdc42 (Zhao et al., 2003; Servotte et al., 2006).
In addition, in small cell lung and prostate cancer cell lines, it has
been shown that NTS can enhance the activity of focal adhesion
kinase (FAK) (Tallett et al., 1996; Lee et al., 2001).
Neurotensin receptor 2, NTSR2
The low afﬁnity receptor of NTS,NTSR2, is a protein of 410 amino
acids, with a high homology toNTSR1 (64%) (Chalon et al., 1996).
NTSR2 exhibits a low binding property for NTS and this binding
can be inhibited by levocabastine, a non-peptide histamine H1
receptor antagonist (Schotte et al., 1986). SR48692, which has a
lower afﬁnity for NTSR2 than for NTSR1, can stimulate the activ-
ity of this receptor (Yamada et al., 1998). When the cloned mouse
NTSR2 coding sequence is expressed in Xenopus laevis ovocytes,
NTS, neuromedin N, levocabastine, and SR48692, are capable of
triggering an inward current which is calcium-dependent (Mazella
et al., 1996). Using CHO cells transfected with the cloned rat or
human NTSR2 cDNA, levocabastine and SR 48692 can mobi-
lize intracellular Ca2+ more intensively than NTS agonists and
phosphorylate Erk1/2, suggesting that NTSR1 and NTSR2 recep-
tors present distinct functional characteristics (Botto et al., 1997;
Yamada et al., 1998; Gendron et al., 2004). InCHOcells transfected
with humanNTSR2 cDNA,bothNTSR1 antagonists, SR48692 and
SR142948A, enhance inositol phosphate (IP) formation with sub-
sequent [Ca2+] immobilization, induce arachidonic acid release,
and stimulate MAPK activity. Interestingly, these activities were
inhibited by NTS and levocabastine in a dose-dependent man-
ner. In summary, the signaling pathway triggered by NTSR2 is
cell-dependent, and mainly based on its overexpression. This
response is far different from that of the physiological endogenous
expression.
Neurotensin receptor 3, gp85/sortilin, NTSR3
NTSR3 functions as a modulator of neurotensinergic signaling
when it is co-expressed with another receptor of NTS, and as
a functional receptor involved in the migration when expressed
alone. This receptor is not NTS-speciﬁc. It can bind other lig-
ands such as lipoprotein lipase, proneurotrophins, protein RAP
(receptor-associated protein), or protein SAP (sphingolipid acti-
vator protein) (Nielsen et al., 1999; Lefrancois et al., 2003). NTSR3
may act as a co-receptor to participate in true NTS/NTSR1
signaling. The study by immunoprecipitation using the adeno-
carcinoma cell line HT29, demonstrated that the NTSR3 forms
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heterodimers with the NTSR1. Additionally, upon NTS stim-
ulation, the NTSR1/NTSR3 complex is internalized and the
interaction between the two receptors modulates both the NTS-
induced phosphorylation of MAPK and the phosphoinositide (PI)
turnover mediated by NTSR1 (Martin et al., 2002).
In the human microglial cell line C13NJ, NTSR3 is the only
known endogenous NTS receptor. In these cells, NTS elicited cell
migration by a mechanism dependent on both PI3K and MAPK
pathways (Martin et al., 2003). The NTS/NTSR3 complex has been
shown to phosphorylate both Erk1/2 and Akt kinases in a murine
microglial cell line (Dicou, 2008).
NEUROTENSIN/NEUROTENSIN RECEPTOR COMPLEX AND
CANCER BIOLOGY
Few years after its discovery, high-level expression of NTS was
found in the plasma of pancreatic tumor patients (Gutniak et al.,
1980). This discovery inspired investigations on the relationship
between NTS and cancer. Many studies have since been performed
to clarify the role of NTS in carcinogenesis in diverse cancer
cells.
PANCREATIC CANCER
Pancreatic cancer is the eighth leading cause of cancer death in the
world (Yabushita et al., 2012). It has the poorest prognosis amongst
all human malignant solid tumors, mainly due to its high rate of
metastasis (Cheng et al., 2012). The growth promoting action of
NTS has been observed in pancreatic cancer cell lines both in
vitro and in vivo. In both cases, the NTSR1 antagonist, SR48692,
inhibited the NTS-induced effects (Sumi et al., 1993; Iwase et al.,
1997). Recently, NTS was shown to protect insulin producing
cells (b-TC3, INS-1E) against apoptosis induced by IL-1b and
staurosporine (STS) (Coppola et al., 2008). NTSR2 and NTSR3
have been shown to be essential for the NTS mediated survival
of these cells (Beraud-Dufour et al., 2009). NTS also inﬂuenced
the migratory ability of pancreatic cancer cells, while NTS signif-
icantly reduced the migration levels of collectively migrating cells
on vitronectin, NTS signiﬁcantly increased the levels of individ-
ually migrating cells (Mijatovic et al., 2007). Thus, NTS-induced
migration is dependent on the extracellular matrix environment
and their respective migratory mode.
COLORECTAL CANCER
Colorectal cancer is the third most common cancer worldwide
and the fourth most common cause of death (Jemal et al., 2011).
NTS stimulates the growth of mouse and human colon cancer
cell lines in tissue culture and after being xenografted into nude
mice (Maoret et al., 1999). In vivo, systemic NTS administration
stimulates tumor size andweight,DNA,RNA,and the protein con-
tents of the murine colon cancer, MC26 (Yoshinaga et al., 1992).
Recently, the expression of NTSR1 was signiﬁcantly correlated
to an increase in the number of tumors when sporadic cancer
was generated in mouse models by inﬂammation. However, no
effect of NTSR1 expression was noticed on the number of aberrant
crypt foci or tumor size, suggesting that the NTS/NTSR1 signal-
ing complex has a major role in tumor progression (Bugni et al.,
2012). NTS is also known to enhance colon cancer cell migra-
tion by increasing IL-8 expression and secretion. These effects
are blocked by NTSR1 antagonists and curcumin, a diet-derived
chemopreventive and/or chemotherapeutic agent which blocks
AP-1 and NF-κB induction (Wang et al., 2006a). The role of IL-8
identiﬁed as an integral part of the metastasis process, was shown
due to its triggering of the release of enzymes [MMPs, and uro-
plasminogen activator (uPA)], responsible for extracellular matrix
degradation (Xie, 2001).
PROSTATE CANCER
Prostate cancer is the most common male malignancy in West-
ern countries and the second most common cause of male
cancer-related death in the UK and USA (Jemal et al., 2011).
The androgen-dependent human prostate cancer LNCaP cell line
has been shown to exhibit an autocrine growth response to NTS
in androgen-deprived only conditions (Sehgal et al., 1994). Vias
et al. (2007) found that long-term anti-androgen treatment of
LNCaP cells produced a sub-line exhibiting upregulated expres-
sion of NTS and NTS receptors, which increased the proliferation
rate, accelerated cell cycle progression, and increased invasive-
ness through Matrigel. These effects are sensitive to NTS siRNA.
NTSR1 expression was found at very high levels in the human
androgen-independent PC3 cell line, derived from prostate can-
cer metastasized to bone. The growth responses of these cells to
NTS were found at concentrations close to human postprandial
blood levels (Seethalakshmi et al., 1997). These studies proposed
that NTS is a potential autocrine, paracrine, and endocrine regula-
tor of prostate cancer growth in humans, after androgen ablation
therapy and during the devastating ﬁnal stages of the disease.
LUNG CANCER
Lung cancer is the most common cause of cancer-related deaths
throughout the world (Jemal et al., 2011). High concentration of
NTS is present in and secreted from half classic small cell lung
cancer cells (SCLC; Moody et al., 1985). NTS is one of the 73
genes overexpressed in the highly metastatic human lung cell line,
H460-M, as compared to control cells (de Lange et al., 2003).
In lung cancer cell lines, NCI-H209 and H345, SR48692 inhib-
ited NTS-mediated calcium mobilization cells and c-fos mRNA
induction and proliferation in a dose-dependent manner (Moody
et al., 1985). SR48692 also inhibited tumor growth of NCI-H209
xenografts.
BREAST CANCER
Breast cancer is the most common cancer in women, and the sec-
ond leading cause of cancer deaths in women worldwide (Jemal
et al., 2011). NTS immunoreactivity has been observed in breast
cancers in vivo. NTSR1 expression has also been demonstrated
in several breast cancer cell lines (Elek et al., 2000). The NTS
anti-apoptotic effect has been described in the cell line MCF-
7 originating from breast adenocarcinoma. Prolonged exposure
to JMV449, a NTS-speciﬁc agonist, protected MCF-7 cells from
serum deprivation-induced death, and reduced the number of
apoptotic cells by two to three times. These effects have been pre-
dicted to be due, in part, to NTS-mediated induction of Bcl-2
mRNA and protein levels which depends on stimulation of MAPK
(Somaï et al., 2002). By using NTSR1 Sh-RNA and SR 48692,
tumor growthwas signiﬁcantly decreasedwhenNTSR1 expression
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was abolished or blocked in experimental tumors of the breast
(Souaze et al., 2006a).
REGULATION OF THE NEUROTENSINERGIC SYSTEM
REGULATION OF NTS
Neurotensin deregulation has been observed in many cancers such
as in colonic adenocarcinomas, small cell lung carcinomas, non-
small cell lung adenocarcinomas, medullary thyroid carcinomas,
and in ﬁbrolamellar HCCs (Baca and Schmidt-Gayk, 1981; Ulich
et al., 1983; Moody et al., 1985; Dammrich et al., 1988; Ehren-
fried et al., 1994). DNA methylation has been shown to play a
crucial role in the expression of the gut endocrine gene neu-
rotensin/neuromedin N (NT/N). In the human hepatoma cell line
Hep G2 cells, methylation of a NT/N promoter construct resulted
in a severe reduction of the promoter activity, whereas treatment
with thedemethylating agent 5-azacytidine-inducedNT/Nexpres-
sion (Dong et al., 1998). These observations have been conﬁrmed
in different human colon cancer cell lines, either expressing or
not the gene coding for NTS (Dong et al., 2000). Interestingly,
NTS gene can be regulated by Ras while expressed. Both wild-type
and activated Ras enhances expression of NTS in the gut-derived
CaCo-2 cell line, by activating the proximalAP-1/CREmotif (Evers
et al., 1995). More recently, the PI3K catalytic subunit, p110alfa,
was demonstrated to negatively regulate NTS secretion in vitro
and in vivo. This process involves several regulatory proteins such
as α-tubulin deacetylase, small GTPase, and kinase D-interacting
substrate (Li et al., 2012).
REGULATION OF NTSR1
The mechanisms involved in NTSR1 deregulation in cancer cells
havebeen studied in the context of colorectal carcinogenesis. These
studies implicate an important role of the Wnt/β-catenin pathway
deregulation. The mutation or loss of the protein APC (adeno-
matous polyposis coli) causes a dysfunction in the degradation of
β-catenin. The accumulation of the latter in the cytoplasm, and
its subsequent translocation to the nucleus induces NTSR1 gene
expression via its association with transcription factors Tcf/Lef (T
cell factor/lymphoid enhancing factor) (Souaze et al., 2006b). The
NTSR1 promoter can be activated by the complex β-catenin/Tcf
because it contains a consensus site for the transcription factors
Tcf. In agreement with this result, it has been demonstrated that
inhibitors of GSK-3β (protein kinase involved in the phosphoryla-
tion of β-catenin and its degradation) which cause the signiﬁcant
accumulation of β-catenin, upregulates the level of NTSR1 tran-
scription (Wang et al., 2010). Similar results have been obtained in
other cancers such as lung, prostate, and breast cancers (Chesire
et al., 2002; Turashvili et al., 2006).
REGULATION OF NTSR1 BY ITS OWN LIGAND
Upon acute agonist exposure, and under physiological conditions,
initiated by β-arrestin-1 (βARR1), and β-arrestin-2 (βARR2), the
NTS/NTSR1 complex is internalized and degraded in lysosomes
through clathrin-coated vesicles. Cell resensitization occurs from
de novo receptor synthesis a few hours after agonist removal
(Souaze and Forgez, 2006; Law et al., 2012). However, some stud-
ies on cellular models such as the murine neuroblastoma cell
line N1E-115 and human colon cancer cell line HT-29, showed
a change in the trafﬁc situation when the cell had a prolonged
exposure to saturating doses of agonist (Souaze et al., 1997; Najimi
et al., 1998). Instead of being degraded in the lysosome, NTSR1
accumulated transiently with NTS in the perinuclear recycling
compartment (PNRC) where it was latter recycled to the plasma
membrane (Toy-Miou-Leong et al., 2004). More recent research
has shown the activity of endothelin-converting enzyme-1 (ECE-
1) and βARRs being crucial for NTSR1 recycling and enhance NTS
degradation (Law et al., 2012). Thus, NTS stimulation induces cel-
lular adaptation by altering the degradation process of NTSR1.
This phenomenon leads to permanently sensitizing cells to the
neurotensinergic signal. The implementation of this mechanism
could lead to deregulation of multiple signaling pathways involved
in the cancer progression such as MAPK and its target genes.
NEUROTENSIN/NEUROTENSIN RECEPTORS AND THERAPY
The implications of the previous sections suggest a more direct
role for NTS/NTSR1 in cancer growth and progression, than has
been previously attributed. Nevertheless, the ability to develop
therapeutic strategies, around this complex, remain a challenge.
Yet, despite them, the characteristics and qualities associated with
this system should provide new pharmaceutical approaches as the
system becomes further studied.
In the periphery and in the central nervous system,NTS mainly
modulates the action of other molecules which are the principal
effectors. Support for this viewwas conﬁrmedby experimentswith
NTS- or NTSRs-deﬁcient mice. These mice do not present any
physiological disorder, are viable, and show normal growth and
overt behavior. The deﬁcient mice were also useful to implicate the
NTS system in body temperature control (Pettibone et al., 2002),
feeding regulation, weight control, and locomotion (Remaury
et al., 2002). Mice were also less responsive or sensitive to exoge-
nous agents or conditions. NTSR1 ko mice were less sensitive to
the anorectic effects caused by leptin (Kim et al., 2008), and less
responsive to morphine-induced analgesia (Roussy et al., 2010).
Experiments with NTSR1- and NTSR2-deﬁcient mice indicate a
role in the regulation of ethanol consumption. However, NTSR1
regulates ethanol intoxication while NTSR2 is involved in ethanol-
induced hypnosis (Lee et al., 2010, 2011). This suggests that the
disruption of NTS system in the periphery is unlikely to generate
side effects superior to the beneﬁts expected in cancer treatment.
On the other hand, the quasi exclusive alteration of theNTS system
in tumors would confer an advantage in its use as a therapeutic
target.
BIOLOGICAL TOOLS USED TO INTERACTWITH THE NTS/NSTR SYSTEMS
Few biological tools have been developed to speciﬁcally target NTS
system. The two most studied ones are the NTSR1 antagonists, SR
48692, and SR142948A (Gully et al., 1996, 1997). These molecules
were developed to counteract NTS effects in central and peripheral
nervous system. For this purpose, both molecules are speciﬁc and
efﬁcient. These compounds have been extensively used to success-
fully counteract exogenous NTS oncogenic actions. Nevertheless,
these molecules remain weak and problematic to use to counteract
intense autocrine regulation. For example, at high concentrations,
SR48692 is toxic for the cells, and as no signiﬁcant information
exists on the biodegradability of these molecules, the dosage levels
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are unknown. In addition, SR 48692 acts as a low afﬁnity agonist
with NTSR2 (Yamada et al., 1998). NTRS2 expression also occurs
in the gastric mucosa, in neuroendocrine cells of the stomach, and
the small and large intestine, and in cells of the exocrine pan-
creas. NTSR2 is rarely detected in human-derived tumors (Schulz
et al., 2006). Recently, NTSR2 was found overexpressed in B cell
leukemia patient’s cells (Saada et al., 2012), and upregulated in
prostate cancer cells luminal phenotype (Swift et al., 2010). It
will be difﬁcult to estimate NTSR2 impact on tumorigenesis until
more information on its expression in human tumors becomes
available.
In contrast, NTSR3 exhibits an ubiquitous expression in nor-
mal and tumoral cells. Its contribution on neoplastic progression
is not known. The exact impact of SR48692 on NTSR3 remains
complex. The most advanced hypothesis is that SR 48692 inhibits
the oncogenic effects through NTSR1, when NTSR1 is expressed
and in conjunction or not with NTSR3. In this context it was
shown that SR 48692 inhibited the tumor growth of colon, breast,
pancreas, and small lung cancer cells xenografted in mice (Iwase
et al., 1997; Maoret et al., 1999; Moody et al., 2001; Souaze et al.,
2006a). SR 48692 counteracts exogenously treated NTS in pan-
creas cells MIA PaCa-2 cells, bearing high and low afﬁnity sites
(Iwase et al., 1997), or circulating NTS as in the case of SW480,
MDA-MB 231, and NCI-H209 cells (Maoret et al., 1999; Moody
et al., 2001; Souaze et al., 2006a). It has to be noted that the use
of SR 48692 does not stop tumor growth, but delays the growth
rate by two to three times. The creation of the experimental tumor
in mice results in tumors having an abnormal ratio (up to 10×)
between the tumor size and body size, an observation uncom-
mon and not seen in human tumors. Summarizing the effects
induced by NTS, at the onset of cancer, NTS acts on the pro-
gression rather than on cellular transformation. Those actions,
mediated by NTS include proliferation, survival, and metastatic
effects. It is, therefore, not surprising to observe that the aboli-
tion of NTS/NTSR1 expression or signaling enhances the effect
of several anti-tumoral treatments. For example, NTSR1 inhibi-
tion efﬁciently sensitized prostate regulation in orthotopic human
tumor xenografts in mice to radiotherapy by signiﬁcantly reduc-
ing tumor size, and in prostate cancer cells bearing NTS autocrine
regulation (Valerie et al., 2011).
Another approach employed in the development of speciﬁc
biological tools, uses Sh-RNA or Si RNA targeting NSTR1. The
total or partial abolition of the target results in a decrease in cel-
lular invasion, migration in HNSCC (Shimizu et al., 2008), or
tumor growth of the human breast cancer cells (Souaze et al.,
2006a). The two experimental designs demonstrate a contribu-
tion of NTS in these oncologic processes, through its interac-
tion with NTRS1. At present, more knowledge is needed on
the distribution and the coupling of NTSR2 in tumoral cells,
as well as on the pharmaceutical tools speciﬁcally inhibiting
NTSR2, to determine if NTSR2 is implicated in any oncogenic
process.
TARGETED APPROACHES FOR NTS/NTSR1
A recent approach under investigation is to use NTSR1-speciﬁc
overexpression as a means to target the delivery of therapeu-
tic or visualizing molecules in tumoral cells. This approach is
made possible since NTSR1 endocytosis permits the introduc-
tion of molecules of interest inside the targeted cell and several
strategies have been developed. In the ﬁrst case, a non-viral gene
transfer particle bearing six NTS molecules covalently bound to
poly-lysine, enabled the transfer of a reporter and therapeutic
gene to those tumor cells expressing NTSR1 when injected in the
tumor or into the blood circulation of xenografted nude mice
(Arango-Rodriguez et al., 2006). Interestingly, both injection sites
showed a high proportion of transfected cells. In a second case,
a therapeutic effect was also detected on experimental neuroblas-
toma tumors transfected with a thymidine kinase gene associated
with ganciclovir. A severe reduction of tumor growth was also
observed (Rubio-Zapata et al., 2009). In the same vein, a protein
interfering with the cell synthesis machinery by inducing irre-
versible ADP-ribosylation of elongation factor 2, exotoxin A, was
fused with NTS. This recombinant protein was able to speciﬁcally
recognize NTSR1 positive cells and to exert a real in vitro cytotoxi-
city (Wick and Groner, 1997). In another strategy, oligo-branched
peptides were used because of their proteolysis resistant nature.
Tetra-branched NTS, armed with 5-FdU, increased in vitro and in
vivo tumoral cell cytotoxicity as compared to the free drug (Falciani
et al., 2010a,b). The same idea was applied to carry the cis,cis,trans-
diamminedichloridodisuccinatoplatinum(IV)–neurotensin bio-
conjugate speciﬁcally to tumor cells. The cytotoxicity of
this molecule was tested on cell proliferation and found
efﬁcient when compared to the non-targeted platinum (Gaviglio
et al., 2012).
Neurotensin-based radiopharmaceuticals have also been devel-
oped for tumor localization and therapy. Several strategies using
different NTSR1 ligands were constructed whose main objectives
were to limit the degradation of the molecule while maintain-
ing the ligand speciﬁcity and a good afﬁnity for NTSRs. Thus,
the analog NT-XIX, with the three enzymatic cleavage sites
stabilized showed a high speciﬁcity for NTSR1. A low accumu-
lation of activity in the kidneys and a proper tumor-to-tissue
ratio radioactivity clearance was observed in vivo, as well as
a decrease in xenograft tumor growth (Garcia-Garayoa et al.,
2009). More recently, new NTS analogs, DOTA-NT-20.3, and
DOTA-NT-20.4 showed promising characteristics for imaging
of NTS receptor-positive tumors and therapy (Alshoukr et al.,
2009, 2011).
NTSR1/NTS COMPLEX EXPRESSION IN HUMAN TUMORS
Several experiments have investigated the expression of NTSR1 in
human tumors, butmost of these studies remain too small or local.
In normal colonic tissue, NTSR1 was not detected by immuno-
histochemistry, whereas in human colonic adenomas expression,
NTSR1 was associated with cytoplasmic beta-catenin localization.
This was one of the ﬁrst suggestions that NTSR1 expression was an
early event in colon carcinogenesis (Souaze et al., 2006b). NTSR1
mRNA expression studied by in situ hybridization showed a higher
level of expression in adenocarcinoma as compared to adenomas.
In addition, a higher intensity of NTSR1 expression was observed
in ﬁltrated adenocarcinomas into and beyond the muscularis pro-
pria as compared with tumors that were localized to the mucosa
or submucosa, suggesting a contribution of NTS/NTSR1 complex
in tumor expansion (Gui et al., 2008).
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In pancreas, NTS binding sites were ﬁrst studied by autora-
diography, and found speciﬁcally in pancreatic cancer but not in
normal pancreas and chronic pancreatitis. Nevertheless, north-
ern blots showed NTSR1 mRNA in normal pancreatic cells, but
an increase of transcript level in chronic pancreatitis and pancre-
atic cancer. Within the tumors, NTSR1 expression was higher in
advanced stages as compared to early stages (Wang et al., 2000).
NTSR1 and NTS protein expression was conﬁrmed by immuno-
histochemistry in normal and tumoral tissue. In this latter case
80% expressed both NSTR1 and NTS (Wang et al., 2011).
More recently, a correlation between NTSR1 or NTS expression
with outcome of the disease was evoked. In non-small lung cancer
cells, NTS and NTSR1 expression were not detectable, whereas
60% of patients with stage 1 adenocarcinoma expressed either
NTS or NTSR1 and 40% expressed both markers. Patients treated
only by surgery did not receive adjuvant therapy and, in this
cohort, NTRS1 expression was correlated with a worse progno-
sis of the disease (Alifano et al., 2010b). In contrast, NTS was
found to be expressed in normal epithelial cells of breast tis-
sue, whereas NTSR1 was absent. In breast invasive carcinomas
high expression of NTSR1 was correlated with pejorative clinical
parameters and disease outcome (Dupouy et al., 2009). In head
and neck squamous cell carcinomas, NTS and NTSR1 mRNA
high levels were signiﬁcantly correlated with higher rates of dis-
tant metastasis as well as with the survival rate (Shimizu et al.,
2008). In normal pleura, NTS and NTSR1 were found in 30 and
77%, respectively. In malignant pleural mesothelioma, expres-
sion increased to 71.1 and 90.4%, respectively. Interestingly in
benign tissue, NTSR1 was located at the cell membrane whereas
in tumoral cells, NTSR1 expression was granular and mainly
restricted to the cytoplasm. The lack of presence at the cell surface
suggested a state of permanent activation. In these cases, NTS high
expression was associated with poor disease outcome (Alifano
et al., 2010a).
CONCLUSION
Cancer is more often regarded as a generalized disease and its
treatment is mainly based on chemotherapy. In openly metastatic
cancers, healing the sick is rarely achieved. In these cases only
a prolongation of survival associated with a better quality of
life can be expected. Therefore, it is necessary to improve our
strategies. Recent treatment developments include the customiza-
tion and selection of drugs speciﬁcally directed against biological
and genetic abnormalities expressed by the tumor. However, as
with conventional chemotherapy, these treatments are still insuf-
ﬁciently targeted and are often accompanied by serious side
effects.
Two potential approaches (amongst others) to improve this sit-
uation include the highlighting of abnormalities speciﬁc to cancer
cells, or the delivery of speciﬁc drugs against these pathological
processes. This latter avenue would allow for effective treatment
without side effects or beneﬁt fromametabolic pathway inwhich it
would be possible to connect conventional medicines and transfer
them inside the cancer cells.
The neurotensin and neurotensin 1 receptor system have pro-
vided insights for certain oncological situations. As seen above,
NTS/NTSR1 is overactive in many tumors (Figure 1). The
development of active antagonists, and those well tolerated by
the patient, in human clinical trials will be a necessary step.
NTS/NTSR1 may also be considered to become a carrier of
chemotherapy drugs for tumor cells. In this regard, platinum salts,
such as cisplatin, whose digestive and renal toxicity is well docu-
mented, are a prime target for the development of such tests. In
all cases, the effectiveness of treatment can only be improved if the
selection of patients is likely to beneﬁt from such treatment. The
last 45 years of work on the NTS/NTSR1 system have allowed for a
better understanding of normal and cancer cells. This system can
be further exploited for therapeutic purposes and for improving
the management of cancer.
FIGURE 1 | Schematic representation of NTS oncogenic effects.
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